EquiReason

EquiReason research coverage

Iovance Biotherapeutics, Inc. IOVA

Healthcare · Biotechnology

24quarters analysed
12SEC filings read
3segments identified
10institutional managers tracked

Segments it reports

The business segments Iovance Biotherapeutics, Inc. reports in its own SEC filings.

  • Single Reportable Segment

Product lines it reports

The product and service lines Iovance Biotherapeutics, Inc. breaks its revenue into.

  • Amtagvi
  • Proleukin

Where its revenue is reported

The geographies Iovance Biotherapeutics, Inc. reports revenue for. How much comes from each is in the product.

  • United States

What we read

The sources behind this company, and how many records of each we hold.

  • Financial statements27
  • Quarterly metric series12
  • Business segments3
  • SEC filings12
  • Deals and transactions1
  • Insider transactions (Form 4)6
  • Institutional positions (13F)7
  • Earnings events1
  • Earnings quality checks5
  • Estimate revisions11
  • Seasonal pattern6
  • Multi-period trajectory7
  • Inflection detection1
  • Fiscal calendar1
  • Index membership4

What we look for

Every company is run through the same checks. Both answers are reported — a signal we looked for and did not find is as much a fact as one we did.

  • Guidance changes2
  • Revenue series13
  • Margin series5
  • Cash flow series24
  • Earnings series24
  • Operating cash flow series24
  • Per-share seriesnot found

This page says how much of Iovance Biotherapeutics, Inc. we have read. What any of it means — the direction, the dates, the evidence and what would overturn it — is inside the product.

Open IOVA in EquiReason

This page publishes coverage counts and reported breakdown names, but no financial figures, price data, rankings or investment conclusions. Sources are SEC filings, earnings calls and public institutional disclosures. How the research is made · All companies

Iovance Biotherapeutics, Inc. (IOVA) — research coverage | EquiReason